TY - JOUR
TI - Impact of tumor site and adjuvant radiotherapy on survival of patients with adenoid cystic carcinoma: A seer database analysis
AU - Tasoulas, J.
AU - Divaris, K.
AU - Theocharis, S.
AU - Farquhar, D.
AU - Shen, C.
AU - Hackman, T.
AU - Amelio, A.L.
JO - Blood cancer journal
PY - 2021
VL - 13
TODO - 4
SP - 1-16
PB - MDPI AG
SN - null
TODO - 10.3390/cancers13040589
TODO - adjuvant radiotherapy;  adult;  age;  aged;  Article;  cancer prognosis;  cancer registry;  cancer staging;  cancer survival;  controlled study;  disease specific survival;  female;  human;  major clinical study;  male;  overall survival;  parotid gland;  salivary adenoid cystic carcinoma;  sublingual gland;  submandibular gland;  survival rate;  tumor localization
TODO - Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor, displaying aggressive behavior with frequent recurrence and metastasis. Little information exists regarding the impact of clinicopathological parameters and adjuvant radiotherapy (aRT) on ACC disease specific (DSS) and overall survival (OS). We extracted demographic, treatment, and survival information of 1439 patients with major or minor intraoral salivary gland ACC from the Surveillance, Epidemiology, and End Results (SEER) database. The associations between tumor characteristics and aRT with OS and DSS were estimated using hazard ratios (HR) and 95% confidence intervals (CI). Submandibular gland ACCs had the worst prognosis (adjusted DSS HR = 1.48; 95% CI = 0.99–2.20, compared to parotid), and this difference was more pronounced among patients with advanced-stage tumors (adjusted DSS HR = 1.93; 95% CI = 1.13–3.30). aRT was associated with increased overall survival only among stage III submandibular ACC patients (HR = 0.64; 95% CI = 0.42–0.98) and had no benefit in any other group. In conclusion, submandibular gland ACC carries a worse prognosis than other gland subsites and may benefit from aRT. The different outcomes between submandibular gland and other major or minor gland ACCs warrant further mechanistic investigation. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
ER -